# SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

> **NCT03443492** · PHASE2 · COMPLETED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 130 (actual)

## Conditions studied

- Locally Advanced or Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** S-1
- **DRUG:** Leucovorin(oral )
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** 5-FU
- **DRUG:** Leucovorin(IV)

## Key facts

- **NCT ID:** NCT03443492
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-26
- **Primary completion:** 2019-11-30
- **Final completion:** 2019-11-30
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2025-12-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443492, "SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03443492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*